Exploratory Study Using Nanotechnology to Detect Biomarkers of Parkinson's Disease From Exhaled Breath

This study is enrolling participants by invitation only.
Sponsor:
Collaborator:
Technion, Israel Institute of Technology
Information provided by (Responsible Party):
Ilana Schlesinger, Rambam Health Care Campus
ClinicalTrials.gov Identifier:
NCT01246336
First received: November 21, 2010
Last updated: May 7, 2014
Last verified: May 2014

November 21, 2010
May 7, 2014
August 2009
January 2016   (final data collection date for primary outcome measure)
Nanosensory detection [ Time Frame: immediate ] [ Designated as safety issue: No ]
analyze combinations of nanomaterial-based sensors (organically functionalized carbon nanotubes and gold nanoparticles)
Not Provided
Complete list of historical versions of study NCT01246336 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Exploratory Study Using Nanotechnology to Detect Biomarkers of Parkinson's Disease From Exhaled Breath
Exploratory Study to Detect Volatile Biomarkers of Idiopathic Parkinson's Disease and Parkinsonism From Exhaled Breath Using a Nanomedical Artificial Olfactory System.

Parkinson's disease is diagnosed clinically, because biomarkers that may help in diagnosis and differential diagnosis are not yet available. Exhaled breath testing may yield a "breath-print" that can be used to distinguish healthy and diseased states.

Not Provided
Observational
Time Perspective: Prospective
Not Provided
Retention:   Samples Without DNA
Description:

Exhaled breath

Probability Sample

Patients diagnosed with Idiopathic Parkinson's disease and Parkinsonism will be included.

  • Parkinson's Disease
  • Parkinsonism
Other: no intervention
no intervention
  • Patients with parkinsonism
    Patients suffering from Parkinson's disease or parkinsonism
  • Healthy controls
    Patients not suffering from Parkinson's disease or any other neurological disorder
    Intervention: Other: no intervention
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Enrolling by invitation
100
January 2016
January 2016   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients with Parkinsonism

Exclusion Criteria:

  • Severe dementia
Both
30 Years and older
Yes
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT01246336
RMB09-0196
No
Ilana Schlesinger, Rambam Health Care Campus
Rambam Health Care Campus
Technion, Israel Institute of Technology
Principal Investigator: Ilana Schlesinger, MD Rambam Health Care Campus
Rambam Health Care Campus
May 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP